Novo Nordisk's CFO expects US growth boost this year

In spite of price pressure in the insulin business and increased US competition Novo Nordisk's CFO expects the company to grow its US business in 2021.

Novo Nordisk CFO Karsten Munk Knudsen | Photo: Novo Nordisk / PR

Novo Nordisk expects to turn its US growth up a notch, since the company is back to growing on this market after a stagnation and price pressure-riddled 2019.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Ambu credits MDR milestone to fastidiousness

All of Medtech firm Ambu’s products already live up to the new EU rules for medical devices, something the firm attributes to a good sense of how much effort living up to the new legislation would require.

China approves Y-mabs drug

Y-mabs’ cancer treatment Danyelza, which is currently licensed to Sciclones, has been approved by the Chinese authorities. Y-mabs will receive double-digit sales royalties.

Further reading

Related articles

Latest news

See all jobs